Taletrectinib
CAS: 1505515-69-4
Ref. 3D-FKC51569
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Product Information
Taletrectinib is a small molecule that inhibits the activity of serine proteases, including caspase-3 and cathepsin B. Taletrectinib binds to the active site of these enzymes, preventing them from cleaving their substrate proteins. It has been shown to have antitumor activity in cell cultures as well as in mice with tumors. This drug has a terminal half-life of about 6 hours in human plasma. The safety profile of taletrectinib is similar to those of other drugs used for cancer treatment. This drug has been tested in phase 1 clinical trials and demonstrated an escalation dose response effect. In addition, it demonstrated a favorable safety profile with limited toxicity profiles. Taletrectinib targets lesions on zymogens that are not accessible by other drugs such as lorlatinib or ibrutinib.br>
br>
Taletrectinib is also being developed for the treatment of neuroendocrine
Chemical properties
Technical inquiry about: 3D-FKC51569 Taletrectinib
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
